Evaluation of Natalizumab for thE Relief of MS Associated FatiGue - Full Text View

Sponsor:	Biogen Idec
Collaborator:	Elan Pharmaceuticals
Information provided by:	Biogen Idec
ClinicalTrials.gov Identifier:	NCT00464074

Purpose

This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

Condition
Multiple Sclerosis

Study Type:	Observational
Study Design:	Observational Model: Case-Only Time Perspective: Prospective
Official Title:	Multi-center, Open-Label Study to Evaluate the Effects of Natalizumab Treatment on Fatigue and Cognition in Subjects With Relapsing Forms of MS

Resource links provided by NLM:

MedlinePlus related topics: Fatigue Multiple Sclerosis

Drug Information available for: Natalizumab

U.S. FDA Resources

Further study details as provided by Biogen Idec:

Primary Outcome Measures:

Visual Analog Scale for Fatigue (VAS-F) [ Time Frame: at three months after initiating treatment with TYSABRI® ] [ Designated as safety issue: No ]

Enrollment:	200
Study Start Date:	September 2007
Study Completion Date:	July 2010
Primary Completion Date:	July 2010 (Final data collection date for primary outcome measure)

Detailed Description:

TYSABRI® treatment has already demonstrated significant improvement in the quality of life (QoL) of patients with MS. In particular, TYSABRI® add-on treatment to interferon beta-1a has demonstrated improvement in fatigue as measured by the Modified Fatigue Impact Scale (MFIS). Both patients and neurologists report that patients have experienced significant improvements in fatigue shortly after initiating TYSABRI® treatment. Fatigue is both a common and a disabling symptom of MS. Further, there is evidence that fatigue contributes to cognitive difficulties in patients with MS. This study aims to study the effects of TYSABRI® treatment on fatigue and cognition in patients with relapsing forms of MS.

The primary objective of this study is to determine the effects of TYSABRI® treatment on fatigue in subjects with relapsing forms of MS as measured by changes in patient-reported Visual Analog Scale for Fatigue (VAS-F).

Primary endpoint is the change in the following:

1. Visual Analog Scale for Fatigue (VAS-F) at three months after initiating treatment with TYSABRI®.

Secondary objectives are to measure changes in patient-reported Modified Fatigue Impact Scale (MFIS) and Fatigue Severity Scale (FSS).

Secondary endpoints are changes in the following:

Modified Fatigue Impact Scale (MFIS)
Fatigue Severity Scale (FSS)

The tertiary objective of this study is to explore for any effects of TYSABRI® treatment on cognition by assessing changes in the Automated Neuropsychology Assessment Metrics (ANAM).

Tertiary endpoints are changes in the Automated Neuropsychology Assessment Metrics (ANAM) consisting of:

Traditional Continuous Performance Test
Running Memory Continuous Performance Test
Simple Response Time
Procedural Response Time
Coding Substitution
Mathematics
Logical Relations
Matching-to-Sample
Stanford Sleepiness Scale

Eligibility

Ages Eligible for Study:	18 Years to 55 Years
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No
Sampling Method:	Non-Probability Sample

Study Population

multicenter clinic patients

Criteria

Inclusion Criteria:

Diagnosis of relapsing forms of MS.
Patients having an inadequate response to or unable to tolerate alternate MS therapies.
Patient must be enrolled in the TOUCH prescribing program.
Recent MRI as part of the TOUCH prescribing program.
Patient must be between 18 and 55 years of age, inclusive.
EDSS between 0 and 5.5, inclusive.
Able to provide written informed consent.
Capable of completing the fatigue (MFIS, FSS, and VAS-F) and cognition (ANAM) sessions.
A baseline VAS-F average score of > 60.
Patient must be naÃƒ-ve to TYSABRI® treatment.

Exclusion Criteria:

Patients not enrolled in the TOUCH prescribing program.
History or presence of progressive multifocal leukoencephalopathy (PML).
Diagnosis of primary progressive MS (PPMS) or secondary progressive MS (SPMS) without relapses.
Immunocompromised in the judgment of the investigator.
Allergy or hypersensitivity to TYSABRI®.
Prior history or current presence of a clinically significant medical illness or laboratory abnormality, including any significant cardiac, endocrinologic, hematologic, hepatic, immunologic, metabolic, urologic, pulmonary, gastrointestinal, dermatologic, psychiatric, renal, and/or other major disease, that, in the opinion of the investigator, would preclude the administration of TYSABRI®.
Women pregnant, breast feeding, or planning to become pregnant and women who are not postmenopausal or surgically sterile, and unwilling to practice contraception.
A baseline average VAS-F score of < 60.
Problems with upper extremity dexterity that could preclude usage of a computer mouse.
With educational completion below 8th grade school equivalent or non-fluent in English.
Any other reason, in the opinion of both the Investigator and/or Sponsor, the patient is determined not suitable for study participation.

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00464074

Show 31 Study Locations

Sponsors and Collaborators

Biogen Idec

Elan Pharmaceuticals

More Information

No publications provided

Responsible Party:	Biogen Idec MD, Biogen Idec
ClinicalTrials.gov Identifier:	NCT00464074 History of Changes
Other Study ID Numbers:	001-06-NAT
Study First Received:	April 18, 2007
Last Updated:	July 7, 2011
Health Authority:	United States: Food and Drug Administration

Keywords provided by Biogen Idec:

fatigue
Tysabri
cognition

Additional relevant MeSH terms:

Fatigue
Multiple Sclerosis
Sclerosis
Signs and Symptoms
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System

Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases
Pathologic Processes

ClinicalTrials.gov processed this record on February 09, 2012